The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
FGF23 induces left ventricular hypertrophy
Open accessAbstract
Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor-dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intramyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF-receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from animal studies and healthy subjects indicate that longer treatment with high Pi can lead to cardiac remodeling in animals and higher blood pressure in humans [19, 35, 42].”
From Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels (2025) · cites this paper as [19]
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Self-citationLang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Self-citationMutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Self-citationA Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J., Antos, C. L., Markham, B. E., Richardson, J. A., Robbins, J. M., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923
Regulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,890
Receptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871
Flagged first, then by citations
1 of the 92 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Ben-Dov, 2007, J Clin Invest., 117, 4003
- Yin, 1982, Am J Physiol., 243, H941
- Nehgme, 1997, J Clin Endocrinol Metab., 82, 2450, 10.1210/jc.82.8.2450 · DOI
Cited by
Sorted by citations
Items 301–400 of 1,002
Pathophysiology of the chronic kidney disease – mineral bone disorder
Hruska, K. A., Seifert, M. E., & Sugatani, T. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000132 · Cited by 77
Why do young people with chronic kidney disease die early?
Kumar, S. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.143 · Cited by 77
Yanochko, G. M., Vitsky, A., Heyen, J. R. R., Hirakawa, B. P., Lam, J. L., May, J. R., Nichols, T., Sace, F., Trajkovic, D., & Blasi, E. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft161 · Cited by 76
Hensel, N., Schön, A., Konen, T., Lübben, V., Förthmann, B., Baron, O., Grothe, C., Leifheit‐Nestler, M., Claus, P., & Haffner, D. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13585 · Cited by 78
Fibroblast Growth Factor 23 and Risk of CKD Progression in Children
Portale, A. A., Wolf, M. S., Messinger, S., Perwad, F., Jüppner, H., Warady, B. A., Furth, S. L., & Salusky, I. B. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02110216 · Cited by 75
Self-citationLiu, K. D., Yang, W. P., Go, A. S., Anderson, A. H., Feldman, H. I., Fischer, M. J., He, J., Kallem, R. R., Kusek, J. W., Master, S. R., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.025 · Cited by 77
Self-citationExhaled volatile substances mirror clinical conditions in pediatric chronic kidney disease
Obermeier, J., Trefz, P., Happ, J., Schubert, J. K., Staude, H., Fischer, D., & Miekisch, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178745 · Cited by 74
Regulation of fibroblast growth factor 23 ( FGF 23) in health and disease
Bär, L., Stournaras, C., Lang, F. J. W., & Föller, M. (2019) · FEBS Letters · doi:10.1002/1873-3468.13494 · Cited by 75
Higuchi, T., Abe, M., Yamazaki, T., Okawa, E., Ando, H., Hotta, S., Oikawa, O., Kikuchi, F., Okada, K., & Soma, M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.010 · Cited by 74
Proteinuria Increases Plasma Phosphate by Altering Its Tubular Handling
de Seigneux, S., Courbebaisse, M., Rutkowski, J. M., Wilhelm-Bals, A., Metzger, M., Khodo, S. N., Hasler, U., Chehade, H., Dizin, É., Daryadel, A., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010104 · Cited by 74
Phosphate as a Pathogen of Arteriosclerosis and Aging
Kuro‐o, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17045 · Cited by 73
Self-citationAn Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk
Vázquez‐Sánchez, S., Poveda, J., Navarro‐García, J. A., González‐Lafuente, L., Rodríguez‐Sánchez, E., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.632260 · Cited by 74
Khosravi, F., Ahmadvand, N., Bellusci, S., & Sauer, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672935 · Cited by 78
Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation
Benz, K., Hilgers, K., Daniel, C., & Amann, K. (2018) · International Journal of Nephrology · doi:10.1155/2018/4310379 · Cited by 73
Parathyroid Hormone: A Uremic Toxin
Duque, E. J., Elias, R. M., & Moysés, R. M. A. (2020) · Toxins · doi:10.3390/toxins12030189 · Cited by 77
The role of vitamin D in cardiovascular disease: From present evidence to future perspectives
Brandenburg, V. M., Vervloet, M. G., & Marx, N. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.005 · Cited by 73
Plasma FGF23 and the risk of stroke
Wright, C. B., Dong, C., Stark, M., Silverberg, S. J., Rundek, T., Elkind, M. S. V., Sacco, R. L., Mendez, A. J., & Wolf, M. S. (2014) · Neurology · doi:10.1212/wnl.0000000000000410 · Cited by 71
Self-citationFGF23 and PTH--double agents at the heart of CKD
Silver, J., Rodríguez, M., & Slatopolsky, E. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs050 · Cited by 73
Serum Fibroblast Growth Factor-23 Is Associated with Incident Kidney Disease
Rebholz, C. M., Grams, M. E., Coresh, J., Selvin, E., Inker, L. A., Levey, A. S., Kimmel, P. L., Vasan, R. S., Eckfeldt, J. H., Feldman, H. I., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014020218 · Cited by 72
Self-citationSmith, E. R., Holt, S. G., & Hewitson, T. D. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.09.009 · Cited by 75
ter Maaten, J. M., Voors, A. A., Damman, K., van der Meer, P., Anker, S. D., Cleland, J. G. F., Dickstein, K., Filippatos, G. S., van der Harst, P., Hillege, H. L., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.010 · Cited by 73
Management of secondary hyperparathyroidism: how and why?
Komaba, H., Kakuta, T., & Fukagawa, M. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1369-2 · Cited by 71
Mortality reduction by post-dilution online-haemodiafiltration: a cause-specific analysis
Nubé, M. J., Peters, S. A. E., Blankestijn, P. J., Canaud, B., Davenport, A., Grooteman, M. P. C., Aşçı, G., Locatelli, F., Maduell, F., Morena-Carrere, M., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw381 · Cited by 71
Acute blood loss stimulates fibroblast growth factor 23 production
Rabadi, S. M., Udo, I., Leaf, D. E., Waikar, S. S., & Christov, M. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00081.2017 · Cited by 74
Prioritising the primary prevention of heart failure
Khan, S. S., Berwanger, O., Fiuzat, M., McMurray, J. J. V., Narula, J., Prabhakaran, D., Sliwa, K. S., Tromp, J., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01393-5 · Cited by 81
Santos, F., Fuente, R., Mejía, N., Mantecón, L., Gil‐Peña, H., & Ordóñez, F. Á. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2364-9 · Cited by 71
Clinkenbeard, E. L., Noonan, M. L., Thomas, J. C., Ni, P., Hum, J. M., Aref, M. W., Swallow, E. A., Moe, S. M., Allen, M. R., & White, K. E. (2019) · JCI Insight · doi:10.1172/jci.insight.123817 · Cited by 71
Stevens, K. K., Denby, L., Patel, R. K., Mark, P. B., Kettlewell, S., Smith, G. L., Clancy, M. J., Delles, C., & Jardine, A. G. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw252 · Cited by 70
Vitamin D and Atherosclerotic Cardiovascular Disease
Hiemstra, T. F., Lim, K. J., Thadhani, R., & Manson, J. E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00194 · Cited by 71
Wohlfahrt, P., Melenovský, V., Kotrč, M., Beneš, J., Jabor, A., Franeková, J., Lemaire, S., Kautzner, J., & Jarolı́m, P. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.05.012 · Cited by 70
Doxorubicin and Trastuzumab Regimen Induces Biventricular Failure in Mice
Milano, G., Raucci, A., Scopece, A., Daniele, R., Guerrini, U., Sironi, L., Cardinale, D. M., Capogrossi, M. C., & Pompilio, G. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.01.014 · Cited by 70
FGF23 and Vitamin D Metabolism
Latic, N., & Erben, R. (2021) · JBMR Plus · doi:10.1002/jbm4.10558 · Cited by 67
Geddes, R. F., Elliott, J., & Syme, H. M. (2015) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13625 · Cited by 69
Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis
Panizo, S., Barrio-Vazquez, S., Naves‐Díaz, M., Carrillo‐López, N., Rodrı́guez, I., Fernández-Vázquez, A., Valdivielso, J. M., Thadhani, R., & Cannata-Andía, J. B. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft268 · Cited by 71
Schaub, J. A., Coca, S. G., Moledina, D. G., Gentry, M., Testani, J. M., & Parikh, C. R. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.07.014 · Cited by 68
Bone-Muscle Mutual Interactions
Lara-Castillo, N., & Johnson, M. L. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00602-6 · Cited by 70
FGF-23 and the Progression of Coronary Arterial Calcification in Patients New to Dialysis
Khan, A. M., Chirinos, J. A., Litt, H. I., Yang, W. P., & Rosas, S. E. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02160212 · Cited by 70
Self-citationTakashi, Y., Kinoshita, Y., Hori, M., Ito, N., Taguchi, M., & Fukumoto, S. (2016) · Endocrine Research · doi:10.1080/07435800.2016.1242604 · Cited by 68
Fibroblast Growth Factor 23 and Klotho in AKI
Christov, M., Neyra, J. A., Gupta, S., & Leaf, D. E. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.10.005 · Cited by 68
Martin, K. J., Pickthorn, K., Huang, S., Block, G. A., Vick, A., Mount, P. F., Power, D. A., & Bell, G. M. (2013) · Kidney International · doi:10.1038/ki.2013.289 · Cited by 67
FGF23, Hypophosphatemia, and Emerging Treatments
Imel, E. A., Biggin, A., Schindeler, A., & Munns, C. F. (2019) · JBMR Plus · doi:10.1002/jbm4.10190 · Cited by 66
Smith, E. R., McMahon, L. P., & Holt, S. G. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0208 · Cited by 67
Arrhythmia and Sudden Death in Hemodialysis Patients
Charytan, D. M., Foley, R. N., McCullough, P. A., Rogers, J., ZIMETBAUM, P. J., Herzog, C. A., & Tumlin, J. A. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09350915 · Cited by 67
Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis
Barnes, J. W., Duncan, D., Helton, S., Hutcheson, S. B., Kurundkar, D., Logsdon, N. J., Locy, M. L., Garth, J. M., Denson, R. S., Farver, C. F., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00246.2018 · Cited by 67
Self-citationBansal, N., Xie, D., Sha, D., Appel, L. J., Deo, R., Feldman, H. I., He, J., Jamerson, K., Kusek, J. W., Messe, S. R., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050514 · Cited by 69
Self-citationRoy, C., Lejeune, S., Slimani, A., de Meester, C., Ahn, S. A., Rousseau, M. F., Amzulescu, M. S., Ginion, A., Ferracin, B., Pasquet, A., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12816 · Cited by 66
Phan, P., Saikia, B. B., Sonnaila, S., Agrawal, S., Alraawi, Z., Kumar, T. K. S., & Iyer, S. (2021) · Cells · doi:10.3390/cells10092418 · Cited by 70
Prié, D., Forand, A., Francoz, C., Elie, C., Cohen, I., Courbebaisse, M., Eladari, D., Lebrec, D., Durand, F., & Friedlander, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066182 · Cited by 66
FGF23 and Klotho in chronic kidney disease
Olauson, H., & Larsson, T. E. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32836213ee · Cited by 68
Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis
Seeherunvong, W., Abitbol, C. L., Chandar, J. J., Rusconi, P. G., Zilleruelo, G. E., & Freundlich, M. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2224-7 · Cited by 66
Chronic kidney disease, heart failure and neprilysin inhibition
Haynes, R., Zhu, D., Judge, P. K., Herrington, W. G., Kalra, P. A., & Baigent, C. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz058 · Cited by 66
Ding, J., Tang, Q., Luo, B., Zhang, L., Li, L., Han, L., Hao, M., Li, M., Yu, L., & Li, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172549 · Cited by 65
Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults
Panwar, B., Jenny, N. S., Howard, V. J., Wadley, V. G., Muntner, P., Kissela, B. M., Judd, S. E., & Gutiérrez, O. M. (2015) · Stroke · doi:10.1161/strokeaha.114.007489 · Cited by 65
Self-citationKovesdy, C. P., & Quarles, L. D. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00606.2015 · Cited by 65
The Importance of Phosphate Control in Chronic Kidney Disease
Tsuchiya, K., & Akihisa, T. (2021) · Nutrients · doi:10.3390/nu13051670 · Cited by 65
Phosphate intake, hyperphosphatemia, and kidney function
Rubio-Aliaga, I., & Krapf, R. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02691-x · Cited by 65
Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease?
Evenepoel, P., Rodríguez, M., & Ketteler, M. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.02.007 · Cited by 65
The Use of Fibroblast Growth Factor 23 Testing in Patients with Kidney Disease
Smith, E. R. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10941013 · Cited by 65
IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4
Huang, Y., Wang, S., Zhou, J., Liu, Y., Du, C., Yang, K., Bi, X., Liu, M., Han, W., Wang, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18519-0 · Cited by 65
Role of fibroblast growth factor signalling in hepatic fibrosis
Seitz, T., & Hellerbrand, C. (2021) · Liver International · doi:10.1111/liv.14863 · Cited by 64
The regulation of FGF23 under physiological and pathophysiological conditions
Rausch, S., & Föller, M. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02668-w · Cited by 70
C-terminal FGF23 is a strong predictor of survival in systolic heart failure
Gruson, D., Lepoutre, T., Ketelslegers, J., Cumps, J., Ahn, S. A., & Rousseau, M. F. (2012) · Peptides · doi:10.1016/j.peptides.2012.08.003 · Cited by 64
Shibata, K., Fujita, S.-I., Morita, H., Okamoto, Y., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073184 · Cited by 64
Phosphate: a stealthier killer than previously thought?
González‐Parra, E., Tuñón, J., Egido, J., & Ortíz, A. (2012) · Cardiovascular Pathology · doi:10.1016/j.carpath.2012.02.008 · Cited by 65
Cardiac actions of fibroblast growth factor 23
Faul, C. (2016) · Bone · doi:10.1016/j.bone.2016.10.001 · Cited by 64
Self-citationEisenga, M. F., van Londen, M., Leaf, D. E., Nolte, I. M., Navis, G. J., Bakker, S. J. L., de Borst, M. H., & Gaillard, S. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121350 · Cited by 65
Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions
Quarles, L. D. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000467 · Cited by 63
Francis, C. P., Courbon, G., Gerber, C., Neuburg, S., Wang, X., Dussold, C., Capella, M., Qi, L., Isakova, T., Mehta, R. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.07.026 · Cited by 64
Self-citationFukagawa, M., Yokoyama, K., Shigematsu, T., Akiba, T., Fujii, A., Kuramoto, T., Odani, M., Akizawa, T., & the ONO-5163 Study Group (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw408 · Cited by 62
Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone
Krieger, N. S., Culbertson, C. D., Kyker‐Snowman, K., & Bushinsky, D. A. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00199.2012 · Cited by 61
Vascular Toxicity of Phosphate in Chronic Kidney Disease
Gross, P., Six, I., Kamel, S., & Massy, Z. A. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0735 · Cited by 65
The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy
Grabner, A., & Faul, C. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000231 · Cited by 61
Self-citationLoutradis, C., Sarafidis, P. A., Papadopoulos, C. E., Papagianni, A. A., & Zoccali, C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017101102 · Cited by 62
Bergmark, B. A., Udell, J. A., Morrow, D. A., Jarolím, P., Kuder, J., Solomon, S. D., Pfeffer, M. A., Braunwald, E., & Sabatine, M. S. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1424 · Cited by 62
Rodelo‐Haad, C., Santamaría, R., Muñoz-Castañeda, J. R., de Mier, M. V. P.-R., Martín‐Malo, A., & Rodríguez, M. (2019) · Toxins · doi:10.3390/toxins11030175 · Cited by 62
Mace, M. L., Ølgaard, K., & Lewin, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228810 · Cited by 63
Bone, inflammation and chronic kidney disease
Mazzaferro, S., Martini, N. D., Rotondi, S., Tartaglione, L., Ureña, P., Bover, J., & Pasquali, M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.040 · Cited by 61
Cardiovascular risk in children: a burden for future generations
Candelino, M., Tagi, V. M., & Chiarelli, F. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01250-5 · Cited by 74
Sarnak, M. J., Auguste, B. L., Brown, E. A., Chang, A. R., Chertow, G. M., Hannan, M. F., Herzog, C. A., Nadeau‐Fredette, A., Tang, W. H. W., Wang, A. Y.-M., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001088 · Cited by 63
FGF-23: the rise of a novel cardiovascular risk marker in CKD
Heine, G. H., Seiler, S., & Fliser, D. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs259 · Cited by 64
Mineral metabolism and cardiovascular disease in CKD
Fujii, H., & Joki, N. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1363-8 · Cited by 61
Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23
Matsui, I., Oka, T., Kusunoki, Y., Mori, D., Hashimoto, N., Matsumoto, A., Shimada, K., Yamaguchi, S., Kubota, K., Yonemoto, S., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.02.018 · Cited by 61
Onal, M., Carlson, A. H., Thostenson, J. D., Benkusky, N. A., Meyer, M. B., Lee, S. M., & Pike, J. W. (2017) · JBMR Plus · doi:10.1002/jbm4.10023 · Cited by 60
Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies
Rangaswami, J., & McCullough, P. A. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.08.005 · Cited by 59
Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH
Liu, E. S., Thoonen, R., Petit, E. T., Yu, B., Buys, E. S., Scherrer‐Crosbie, M., & Demay, M. B. (2018) · Endocrinology · doi:10.1210/en.2018-00174 · Cited by 59
The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
Heijboer, A. C., & Cavalier, E. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-00987-9 · Cited by 59
FGF 23 is associated with disease severity and prognosis in chronic heart failure
Poelzl, G., Trenkler, C., Kliebhan, J., Würtinger, P., Seger, C., Kaser, S., Mayer, G. J., Pirklbauer, M., Ulmer, H., & Griesmacher, A. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12349 · Cited by 58
Osteocytic FGF23 and Its Kidney Function
Agoro, R., Ni, P., Noonan, M. L., & White, K. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00592 · Cited by 59
Slavić, S., Ford, K., Modert, M., Becirovic, A., Handschuh, S., Baierl, A., Katica, N., Zeitz, U., Erben, R. G., & Andrukhova, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-10140-4 · Cited by 58
Barreto, F. C., Stinghen, A. E. M., de Oliveira, R. B., Franco, A. T. B., Moreno, A. N., Barreto, D. V., Pecoits‐Filho, R., Drüeke, T. B., & Massy, Z. A. (2014) · Brazilian Journal of Nephrology · doi:10.5935/0101-2800.20140033 · Cited by 57
Kawai, M., Kinoshita, S., Kimoto, A., Hasegawa, Y., Miyagawa, K., Yamazaki, M., Ohata, Y., Ozono, K., & Michigami, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.410043 · Cited by 58
Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure
Maizel, J., Six, I., Dupont, S., Secq, E., Dehédin, B., Barreto, F. C., Benchitrit, J., Poirot, S., Slama, M., Tribouilloy, C. M., et al. (2013) · Kidney International · doi:10.1038/ki.2013.110 · Cited by 58
Intercellular Communication Lessons in Heart Failure
Bang, C., Antoniades, C. A., Antonopoulos, A. S., Eriksson, U., Franssen, C., Hamdani, N., Lehmann, L., Moessinger, C., Mongillo, M., Muhl, L., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.399 · Cited by 57
Martin, K. J., Bell, G. M., Pickthorn, K., Huang, S.-C., Vick, A., Hodsman, P., & Peacock, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft417 · Cited by 58
FGF-23 and cardiovascular disease: review of literature
Batra, J., Buttar, R. S., Kaur, P., Kreimerman, J., & Melamed, M. L. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000294 · Cited by 62
FGF23 beyond Phosphotropic Hormone
Takashi, Y., & Fukumoto, S. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.08.006 · Cited by 58
Management of X-linked hypophosphatemia in adults
Lecoq, A.-L., Brandi, M. L., Linglart, A., & Kamenický, P. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154049 · Cited by 58
Chang, A. R., & Grams, M. E. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.04.028 · Cited by 58
Significance of the anti-aging protein Klotho
Dërmaku‐Sopjani, M., Kolgeci, S., Abazi, S., & Sopjani, M. (2013) · Molecular Membrane Biology · doi:10.3109/09687688.2013.837518 · Cited by 59
FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock
Pöss, J., Mahfoud, F., Seiler, S., Heine, G. H., Fliser, D., Böhm, M., & Link, A. (2013) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872613494025 · Cited by 57
Metadata
- Authors
- Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E. Z., Chen, J., Go, A. S., Rosas, S. E., Nessel, L., Townsend, R. R., Feldman, H. I., St. John Sutton, M., Ojo, A., Gadegbeku, C., Di Marco, G. S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J. A., Moe, O. W., Kuro-o, M., Kusek, J. W., Keane, M. G., & Wolf, M.
- Affiliations
- University of Miami (US)
- The University of Texas Southwestern Medical Center (US)
- University of Alabama at Birmingham (US)
- Harvard University (US)
- University of Illinois Chicago (US)
- Wake Forest University (US)
- Tulane University (US)
- University of California, San Francisco (US)
- University of Pennsylvania (US)
- University of Michigan (US)
- Temple University (US)
- University of Münster (DE)
- National Institutes of Health (US)
- ORCID
- Faul, Christian
- Amaral, Ansel P.
- Isakova, Tamara
- Gutiérrez, Orlando M.
- Lincoln, Joy
- Hare, Joshua M.
- Mundel, Peter
- Scialla, Julia
- Fischer, Michael
- Soliman, Elsayed Z.
- Chen, Jing
- Go, Alan S.
- Rosas, Sylvia E.
- Townsend, Raymond R.
- Feldman, Harold I.
- Ojo, Akinlolu
- Reuter, Stefan
- Kentrup, Dominik
- Tiemann, Klaus
- Hill, Joseph A.
- Moe, Orson W.
- Keane, Martin G.
- Wolf, Myles
- Venue
- Journal of Clinical Investigation
- Published
- 2011-11-01
- Volume
- 121
- Issue
- 11
- Pages
- 4393-4408
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3204831
- OpenAlex
- W2015668150
- Cited by
- 2,027
- References
- 92
- Citations by year
- 2026: 83 · 2025: 92 · 2024: 81 · 2023: 124 · 2022: 135 · 2021: 172 · 2020: 126 · 2019: 144 · 2018: 175 · 2017: 152 · 2016: 154 · 2015: 152 · 2014: 170 · 2013: 155 · 2012: 104
- FWCI
- 107.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- American Heart Association
- Abbott Laboratories
- Amgen
- Nephcure Foundation
- University of Miami
- University of Pennsylvania
- Health Services Research and Development
- Cleveland Clinic
- Cleveland Clinic Foundation
- Johns Hopkins University (RR025005)
- University of Texas Southwestern Medical Center
- Case Western Reserve University (UL1RR024989)
- Deutsches Krebsforschungszentrum
- Ministry of Education, India
- Stifterverband
- National Institutes of Health (RR024131, RR025005, RR05096, RR024989)
- University of Illinois at Urbana-Champaign
- University of California, San Francisco
- Leonard M. Miller School of Medicine
- National Institute on Aging (R01AG019712)
- National Institute of Diabetes and Digestive and Kidney Diseases (5U01DK06102, R01DK076116, K24DK062234, U01DK060990, 5U01 DK60980, (P30-DK-07938, R01DK081374, R01DK062472, F30DK091057, K23DK081673, K23DK087858, R01DK091392, RR024986, R01DK091218, R01DK092461, U01DK060984, U01DK060902, U01DK060980, U01DK060963, U01DK061021, U01DK061028)
- National Center for Research Resources (UL1RR024131, RR-05096, UL1RR024989, UL1RR025005, RR 024131, M01RR016500, UL1RR024986, UL1RR024134, UL1RR029879, M01RR005096, M01RR 16500, M01RR000042)
- Topics
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- fibroblast growth factor 23, left ventricular hypertrophy, chronic kidney disease, calcineurin/NFAT signaling, fibroblast growth factor receptor, cardiomyocyte hypertrophy, cardiovascular disease
- MeSH terms
- Fibroblast Growth Factor-23, Klotho Proteins, Adult, Aged, Animals, Disease Models, Animal, Female, Fibroblast Growth Factors, Glucuronidase, Humans, Kidney Failure, Chronic, Male, Mice, Inbred C57BL, Middle Aged, Models, Cardiovascular, Prospective Studies, Recombinant Proteins, Cohort Studies, Signal Transduction, Fibroblast Growth Factor 2, Hypertrophy, Left Ventricular, Receptors, Fibroblast Growth Factor, Mice, Knockout, Myocytes, Cardiac, Mice, Rats, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
